The Biobanking CF-PF coordinates sample collection, sample processing, cell isolations, LSC purification, sample distribution, and sample storage. One major aim of the Biobanking CF-PF is to establish and provide a robust high-quality collection of primary cell samples derived from a representative cohort of patients in each type of MPN (Ph+ CML, JAK2 V617F+ MPN, KIT D816V+ ASM/MCL, FIP1L1/PDGFRA+ CEL). Patient-derived cell material (PB or BM) are processed by standard techniques to obtain leukocytes or leukocyte subpopulations such as MNC or LSC, and to isolate total RNA, genomic DNA, or other nucleic acids (miRNAs).
In addition, plasma samples are collected to facilitate analyses of circulating cell-free DNA. In each case, cell samples are examined for the presence of putative (CD34+/CD38+ and CD34+/CD38-) stem and progenitor cells by flow cytometry. Whenever possible, these cell fractions are isolated by high speed-sorting and stored as intact cells. The collection and storage of samples and the isolation and use of LSC derived from MPN patients have been approved by the ethics committee of the Medical University of Vienna.
The coordinator of the Biobanking CF-PF, Christine Mannhalter, is supported by members of the Department of Laboratory Medicine, primarily Gregor Hörmann.